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Abstract
Background: Recently, methods for measurement of dioxins in the blood have improved. Also, techniques for 
analyzing large quantities of data have been developed, such as data mining. Even in subjects with elusive 
characteristics, it is becoming possible to find previously unknown characteristics by checking all combinations of 
symptoms.
Findings: Using association analysis of the data mining technique, we extracted and compared combinations with a 
strong relationship between recent symptoms (2001-2004) and recent blood PeCDF levels, and between past 
symptoms (1986-1989) and recent PeCDF levels, in physical, blood, dermatological, dental and ophthalmological 
examinations.
Patients with a higher PeCDF level were more likely to present with symptoms included in the diagnostic criteria, such
as pigmentation. In addition, we obtained evidence that recent PeCDF levels had a stronger relationship with recent
than past symptoms.
Conclusions: Recent PeCDF levels should not be compared directly with past symptoms. However, as the excretion 
rate of PeCDF has been constant, it is probable that PeCDF levels were higher in the past if recent PeCDF levels were 
also high. The study confirmed a relationship between past PeCDF levels and past clinical symptoms. For symptoms 
included in the diagnostic criteria, there was a stronger relationship between PeCDF levels and past symptoms than 
recent symptoms. Alleviation of symptoms in each patient or aging weakened the relationship between PeCDF levels 
and symptoms.
Background
K a n e m i  Y u s h o  i s  a  f o r m  o f  f o o d  p o i s o n i n g  t h a t  w a s
caused by rice bran oil in 1968 in Western Japan, espe-
cially in Northern Kyushu [1]. Initially, polychlorinated
biphenyls (PCBs), which are used as a heat medium in the
process of rice bran oil manufacture, were considered as
the causative agents. However, subsequent research
threw suspicion on 2,3,4,7,8-penta-chlorodibenzofurans
(PeCDFs), which are dioxins that result from heat-dena-
tured PCB, as causative agents. Today, PCBs and their
derivatives are considered to be the main causative agents
of Kanemi Yusho [1-5].
With recent advances in measurement techniques for
dioxins such as PeCDF, measurement of blood PeCDF
levels has become possible using the same amount of
blood as that used in the annual examinations. Since the
Yusho examinations in 2001, PeCDF measurement has
started for patients who wish such an examination [6,7].
A few decades have passed since the occurrence of
Kanemi Yusho, and the symptoms at the initial phase
have already disappeared. We have reported previously
the relationship between clinical symptoms of Yusho
patients and dioxins, one of the causative agents of Yusho
[8,9]. Until now, collective results that show the relation-
ship between Yusho and its symptoms have been
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reported [10]. In addition, several reports have compared
these results [2]. Direct comparison of the latest and pre-
vious reports is difficult because study patients may have
differed between the studies. In addition, it is difficult to
differentiate between patients' low exposure to PeCDF,
when the incident occurred, and amelioration of symp-
toms over time.
Recently, methods for mass data analysis, e.g. data min-
ing, have improved markedly. In particular, it has become
possible to scrutinize and evaluate many combinations of
symptoms which had been considered too large to handle
previously [11]. This study used data mining to investi-
gate the relationship between recent/past symptoms and
PeCDF levels in the same patients, and the relationship
between PeCDF levels and symptoms at a time close to
the occurrence of Kanemi Yusho. It is currently difficult
to distinguish the characteristic Yusho symptoms from
aging symptoms. As a result of the long half-life of
PeCDF, patients who ingested a large amount of PeCDF
at the time of the accident still have high levels of PeCDF,
albeit with a gradual reduction over time.
We think that the association between the symptoms
and PeCDF level can be examined more properly by using
data from the period when the characteristic Yusho
symptoms were still evident. This study aimed to confirm
the association between PeCDF level and Yusho symp-
toms, which recently seems to have become obscured, by
using historical data.
Methods
Subjects and examination items
After the occurrence of Kanemi Yusho, health examina-
tions for designated Yusho patients (hereinafter referred
to as Yusho examinations) have been conducted since
1986. We used data on the presence or absence of symp-
toms in physical, blood, dermatological, dental and oph-
thalmological examinations in Yusho patients who had
undergone annual examinations in 1986-1989 and 2001-
2004, at least once in each period, and whose PeCDF lev-
els were measured. Subjects included both designated
and undesignated patients. The number of subjects who
underwent examinations in both periods was 302. To
analyze the relationship with recent PeCDF levels, repre-
sentative values were obtained for each item in the physi-
cal, blood, dermatological, dental and ophthalmological
examinations for each year in 1986-1989 and 2001-2004,
for each patient. We defined abnormality as one or more
abnormal values in 4 years. Yusho examinations consisted
of a total of 241 items, including 52 items in a question-
naire, 55 in physical and laboratory examinations, 21 in
dermatological examinations, 108 in dental examina-
tions, and five in ophthalmological examinations [1,7].
Methods for data analysis
We found laboratory parameters that were related
strongly to recent PeCDF level among the past and recent
data. We used association analysis [12] to identify symp-
toms that were strongly related to PeCDF level. Associa-
tion analysis was applied in medical domain [8,13]. The
numerical value that indicated the level of association
with PeCDF level was compared between the strongly
associated past and recent symptoms. The proportion of
patients with high PeCDF levels and those with each
symptom were calculated. If a high level of PeCDF and
the presence of each symptom were not related, the rate
of patients with a certain symptom among those with
high PeCDF levels was calculated as the product of both
proportions, and is binomially distributed. If the sample
size was adequate, the binomial distribution could be
considered as a normal distribution. The relation of
symptom to the PeCDF level was judged based on how
the symptom was distributed in the probability distribu-
Table 2: Past symptoms with independently high relationship with high PeCDF level (≥ 50 pg/g lipid)
Symptoms Rate of patients with 
symptom
Rate of patients with high 
PeCDF
Z score
PCB pattern (A) 0.427 0.791 3.891
Uric acid (high) 0.205 0.758 2.135
PCB pattern (B) 0.272 0.707 1.846
Table 1: Recent symptoms with independently high relationship with high PeCDF level (≥ 50 pg/g lipid)
Symptoms Rate of patients with 
symptom
Rate of patients with high 
PeCDF
Z score
PCB pattern (A) 0.411 0.774 3.513
Past pigmentation (+) 0.487 0.667 1.901
Uric acid (high) 0.301 0.692 1.755Matsumoto et al. BMC Research Notes 2010, 3:129
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tion. Z-score was used to show the difference from the
mean in the normal distribution [8]. Association analysis
revealed highly-related combinations of symptoms and
PeCDF levels, which were defined as a z score ≥ 1.645
(one-tailed significance level, 5%).
Classification of examination results
Designation of Yusho was based upon the diagnostic cri-
teria in Additional File 1[1]. The diagnostic criteria
largely consist of "onset conditions," "important findings"
and "reference symptoms and findings." Among these,
severity of "acneform eruptions" and "pigmentation"
("important findings") was determined differently by the
doctors who conducted the examinations, whereas mea-
surement of "abnormalities of blood PCB properties and
levels," "abnormalities of blood polychlorinated quarter-
phenyl (PCQ) properties and levels" and "abnormalities of
blood PeCDF levels" can be expressed numerically,
thereby playing an important role in determining desig-
nation.
To conduct association analysis, the numerical data
were classified into categorical data such as "within the
normal range" and "abnormal values". For general blood
examination, standard values that the study group used in
examinations were used to define "normal range". Find-
ings from the physical, dermatological, dental and oph-
t halmological e xamina tions were each classified by the
presence or absence of abnormalities, and their strength.
With regard to PCBs, it is known that chromatographic
analysis patterns in Yusho patients differ from those in
the general population. Patterns are classified into four
types: Type A, which is specific to Yusho patients; Type
C, which is specific to the general population; Type B,
which is intermediate between Types A and C; and Type
BC, which is intermediate between Types B and C.
For PCQ levels, it was considered that ≥ 0.1 ppb was
abnormally high; ≤ 0.02 ppb (detection limit) was normal;
and 0.03-0.09 ppb was borderline. As for PeCDF level, "50
pg/g lipid or above" and < 50 pg/g lipid were classified as
high and normal level, respectively.
Results
Table 1 indicates the recent symptoms that were indepen-
dently highly related to recent high PeCDF level (≥ 50 pg/
g lipid): Type A PCB pattern, past pigmentation, and high
uric acid level.
Table 2 indicates the past symptoms that were highly
related to recent high PeCDF level (≥ 50 pg/g lipid): Type
A and B PCB pattern, and high uric acid level.
Table 3 compares the z score between recent and past
symptoms that were highly related to recent high PeCDF
level (≥ 50 pg/g lipid). Recent symptoms had a lower z
score than past symptoms for Type A PCB pattern and
high uric acid level. Type B PCB pattern was more
strongly related to past than recent symptoms.
Table 4: Recent symptoms with independently low relationship with low PeCDF level (< 50 pg/g lipid)
Symptoms Rate of patients with 
symptom
Rate of patients with high 
PeCDF
Z score
PCB pattern (C) 0.185 0.893 5.439
Odontogenesis imperfecta (+) 0.017 1.000 1.930
Hepatomegaly (+) 0.073 0.682 1.795
Urinary protein (abnormal) 0.142 0.605 1.756
Nutrition (thin) 0.023 0.857 1.710
Inorganic phosphorus (low) 0.040 0.750 1.677
Palpebral conjunctiva 
pigmentation (+ or above)
0.070 0.667 1.646
Table 3: Comparison of z score of symptoms with high relationship with PeCDF level (≥ 50 pg/g lipid)
Past Recent
PCB pattern (A) 3.891 3.513
Uric acid (high) 2.135 1.755
PCB pattern (B) 1.846 ≤ 1.645
Past pigmentation (+) ≤ 1.645 1.901
≤ 1.645 indicates lack of significant association.Matsumoto et al. BMC Research Notes 2010, 3:129
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Table 4 indicates the recent symptoms that were inde-
pendently highly related to recent low PeCDF level (< 50
pg/g lipid). Type C PCB pattern showed the strongest
relationship, and there was also a strong relationship with
odontogenesis imperfecta.
Table 5 indicates past symptoms that were indepen-
dently highly related to recent low PeCDF level (< 50 pg/g
lipid). Type C PCB pattern showed the strongest relation-
ship, and high albumin level also appeared as a symptom.
Table 6 compares the z score between recent and past
symptoms that were highly related to recent low PeCDF
level (< 50 pg/g lipid). Recent symptoms had a lower z
score than past symptoms for Type C PCB pattern, there-
fore, it was more strongly related to past than recent
symptoms. In addition, odontogenesis imperfecta and
hepatomegaly appeared only as past symptoms.
Figure 1 shows the prevalence of a high level of uric
acid. This was more strongly associated with PeCDF ≥ 50
pg/g lipid than < 50 pg/g lipid, both as a past and recent
symptom. The prevalence was increased in patients with
PeCDF ≥ 50 pg/g lipid and < 50 pg/g lipid. The odds ratio
of prevalence between the PeCDF ≥ 50 pg/g lipid and < 50
pg/g lipid groups was 2.93 in the past. The odds ratio was
2.15 in the recent period.
Discussion
Type A PCB pattern was strongly related to high PeCDF
level (≥ 50 pg/g lipid), and Type C pattern was strongly
related to low PeCDF level (< 50 pg/g lipid). In addition,
the results showed that Type B PCB pattern was related
to high PeCDF level in the past, but there was no such
tendency more recently. Specifically, the results suggested
a stronger relationship with the past than with the recent
PCB pattern. In the past, measuring trace dioxins was dif-
ficult. Gas chromatography was used to measure mass
per molecular weight as a relative amount. PCB patterns
were determined based on peaks, i.e., molecular weights
at which relative amounts increase. PCB pattern Type A
is known to be specific to Yusho, Type C is found in the
general population, and Type B is intermediate between
Table 6: Comparison of z score of symptoms with low relationship with low PeCDF level (< 50 pg/g lipid)
Symptoms Past Recent
PCB pattern (C) 5.439 4.937
Odontogenesis imperfecta (+) 1.930 ≤ 1.645
Hepatomegaly (+) 1.795 ≤ 1.645
Urinary protein (abnormal) 1.756 ≤ 1.645
Nutrition (thin) 1.710 ≤ 1.645
Inorganic phosphorus (low) 1.677 ≤ 1.645
Palpebral conjunctiva pigmentation (+ or 
above)
1.646 ≤ 1.645
Smoking state (+) ≤ 1.645 2.623
Albumin (high) ≤ 1.645 2.019
Inferior gingival pigmentation (brown) ≤ 1.645 1.968
Blood glucose (low) ≤ 1.645 1.771
Total bilirubin (high) ≤ 1.645 1.659
≤ 1.645 indicates lack of significant association.
Table 5: Past symptoms with independently low relationship with low PeCDF level (< 50 pg/g lipid)
Symptoms Rate of patients with 
symptom
Rate of patients with high 
PeCDF
Z score
PCB pattern (C) 0.182 0.855 4.937
Smoking state (+) 0.169 0.667 2.623
Albumin (high) 0.046 0.786 2.019
Inferior gingival pigmentation 
(brown)
0.162 0.612 1.968
Blood glucose (low) 0.033 0.800 1.771
Total bilirubin (high) 0.119 0.611 1.659Matsumoto et al. BMC Research Notes 2010, 3:129
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these two. These PCB patterns are presumed to change
with time, becoming closer to that of the general popula-
tion.
In addition, there was a relationship between uric acid
and past pigmentation, which was one of the diagnostic
criteria. This suggests that there was pigmentation in the
past, and recent symptoms are expected to change into
past symptoms. With regard to uric acid level, the recent
odds ratio is smaller than the past odds ratio. This sug-
gests that the difference in PeCDF level was more
strongly associated with uric acid level in the past. No
relationship has been found for uric acid in previous
studies. Here, the patients who presented with at least
one abnormality during the study period were considered
to have abnormal measurements. Uric acid is a test item
that varies greatly among individuals. A stronger correla-
tion with PeCDF values is found in male than in female
subjects. In female subjects, uric acid is more likely to be
judged as abnormal because of its small normal range,
which may lead to the contingent results. In the present
study, to find combinations of symptoms sensitively while
symptoms were disappearing, patients were designated as
abnormal when they presented with at least one abnor-
mality. The results should be considered in view of the
contingency of this report.
In patients with low PeCDF (< 50 pg/g lipid), inferior
gingival pigmentation (brown) appeared as a recent but
not a past symptom. Development of marked symptoms
in patients with lower recent PeCDF levels is unlikely
from a medical standpoint, therefore, some other causes
are assumed (e.g., pigmentation was determined differ-
ently by the doctors who conducted the examinations).
Measurement of PeCDF level has only commenced
recently. In the present study, recent PeCDF levels and
past symptoms were compared. Fundamentally, there is a
problem with direct comparison between recent PeCDF
levels and past symptoms, because they are from different
t i m e s .  H o w e v e r ,  w e  c o n s i d e r  t h a t  c o m p a r i s o n  i s  v a l i d
because the excretion rate of PeCDF has been constant
over time [1], and this was a cohort study that allowed
identification of each patient in the annual examinations.
Limitations
There was no direct relationship between past symptoms
and recent measurements because of problems with the
excretion rate of PeCDF, therefore, the levels should be
considered as reference values. In addition, patients
might have been exposed to organochlorine compounds
between the periods compared: i.e. 1986-1989 and 2001-
2004. However, it can be assumed that the level of such
exposure would have been far lower than the level that
was already present in Yusho patients. Furthermore,
there might be other diseases that can develop in associa-
tion with aging and other factors. It is unlikely that
another disease was involved, but we will be able to clar-
ify this by further investigating the symptoms observed in
this study.
Conclusion
In this analysis, we studied the relationship between
recent PeCDF levels and recent/past symptoms. The past
symptoms in patients with high PeCDF levels were simi-
lar to the symptoms described in the diagnostic criteria of
Y usho. Patients with recent high PeCDF levels also had
past high PeCDF, and a relationship with past symptoms
is therefore assumed. Past symptoms were demonstrated
to have a stronger relationship with PeCDF level than
were recent symptoms. Alleviation of symptoms in each
patient, or an increase in symptoms because of aging, was
shown to decrease the clarity of symptoms.
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Figure 1 Prevalence of high level of uric acid.
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